rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SNSE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Faeth selloff ‘disproportionate’ to data, says Lucid Capital
      Nov 10Yahoo FinanceSNSE
      Faeth Therapeutics Reports 33% Response Rate in Phase 2 PIKTOR Trial for Advanced Endometrial Cancer
      Nov 9Yahoo FinanceSNSE
      Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
      Nov 3Yahoo FinanceSNSE
      Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
      Oct 27Yahoo FinanceSNSE
      Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
      Oct 23Yahoo FinanceSNSE
      Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 22Yahoo FinanceSNSE
      Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
      Oct 19Yahoo FinanceSNSE
      Faeth Therapeutics' PIK-201 Readout to Serve as Major Inflection Point, Oppenheimer Says
      Oct 7Yahoo FinanceSNSE
      Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout
      Oct 7Yahoo FinanceSNSE
      Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

      AUSTIN, Texas, September 17, 2026--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.

      Sep 17Yahoo FinanceSNSE
      Faeth stock gets new Buy at Guggenheim (FTH:NASDAQ)
      Sep 16Seeking AlphaSNSE
      Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

      AUSTIN, Texas, September 08, 2026--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD (NYU Langone Health & Scientific Co-founder, Faeth Therapeutics), who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human canc

      Sep 8Yahoo FinanceSNSE
      Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

      BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery...

      Aug 28BarchartSNSE

      This is the newest page. Registered accounts read further back.